Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACHE | P22303 | 1/20 | 0.33 |
| ▸ | BACE1 | P56817 | 1/20 | 0.33 |
| ▸ | GPR84 | Q9NQS5 | 9/20 | 0.33 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.32 |
| ▸ | TYMP | P19971 | 3/20 | 0.32 |
| ▸ | MAPT | P10636 | 2/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | THRB | P10828 | 1/20 | 0.31 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7397359 | 0.93 | DAO (0.31) | — | |
| SCHEMBL21144513 | 0.77 | ALDH1A1 (0.40) | ACHEKCNH2ALDH1A1THRBKMT2A | |
| SCHEMBL10781823 | 0.77 | ALDH1A1 (0.40) | ACHEKCNH2ALDH1A1THRBKMT2A | |
| SCHEMBL9400047 | 0.70 | GPR84 (0.38) | ACHEBACE1GPR84KCNH2TYMP | |
| SCHEMBL5144274 | 0.68 | GPR84 (0.34) | ACHEBACE1GPR84KCNH2TYMP | |
| SCHEMBL5601709 | 0.64 | KCNH2 (0.35) | ACHEGPR84KCNH2ALDH1A1TDP1 | |
| SCHEMBL725721 | 0.61 | TYMP (0.47) | ACHEBACE1GPR84TYMPMAPT | |
| Hexane SCHEMBL1134655 | 0.59 | — | — | |
| Hexane SCHEMBL28456468 | 0.59 | TSHR (0.78) | ALDH1A1THRBKMT2A | |
| Hexane SCHEMBL584921 | 0.59 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 47 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| JP-63170313-A | — | — | None | — | — | JP | disclosed |
| JP-63170312-A | — | — | None | — | — | JP | disclosed |
| US-9687476-B2 | Bisaryl-bonded aryltriazolones and use thereof | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2017-06-27 | — | — | US | disclosed |
| EP-2539326-B1 | BISARYL-BONDED ARYLTRIAZOLONES AND USE THEREOF | BAYER IP GMBH (DE) | 2017-05-03 | — | — | EP | disclosed |
| US-20160051518-A1 | BISARYL-BONDED ARYLTRIAZOLONES AND USE THEREOF | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2016-02-25 | — | — | US | disclosed |
| US-9187466-B2 | Bisaryl-bonded aryltriazolones and use thereof | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2015-11-17 | — | — | US | disclosed |
| EP-2619188-B1 | SUBSTITUTED N-PHENETHYLTRIAZOLONEACETAMIDES AND USE THEREOF | BAYER IP GMBH (DE) | 2015-05-06 | — | — | EP | disclosed |
| EP-2619188-A1 | SUBSTITUTED N-PHENETHYLTRIAZOLONEACETAMIDES AND USE THEREOF | Bayer Intellectual Property GmbH (DE) | 2013-07-31 | — | — | EP | disclosed |
| US-20130190330-A1 | BISARYL-BONDED ARYLTRIAZOLONES AND USE THEREOF | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2013-07-25 | — | — | US | disclosed |
| EP-2539326-A1 | BISARYL-BONDED ARYLTRIAZOLONES AND USE THEREOF | Bayer Intellectual Property GmbH (DE) | 2013-01-02 | — | — | EP | disclosed |
| EP-0273310-A3 | 5-ARYL-3H-1,2,4-TRIAZOL-3-ONES AND THEIR USE AS ANTICONVULSANTS | MERRELL PHARMACEUTICALS INC. (US) | 1991-01-09 | — | — | EP | disclosed |
| EP-0273309-A3 | 5-ARYL-3H-1,2,4-TRIAZOL-3-ONES AND THEIR USE IN THE TREATMENT OF NEURODEGENERATIVE DISORDERS | MERRELL DOW PHARMACEUTICALS INC. (US) | 1991-01-09 | — | — | EP | disclosed |
| JP-S63170312-A | USE OF 5-ARYL-3H-1,2,4-TRIAZOL-3-ONES FOR NEUROTIC DEGENERATION LESION | MERRELL DOW PHARMA | 1988-07-14 | — | — | JP | disclosed |
| JP-S63170313-A | ANTISPASMODIC USE OF 5-ARYL-3H-1,2,4-TRIAZOL- 3-ONES | MERRELL DOW PHARMA | 1988-07-14 | — | — | JP | disclosed |
| EP-0273309-A2 | 5-Aryl-3H-1,2,4-triazol-3-ones and their use in the treatment of neurodegenerative disorders | MERRELL DOW PHARMACEUTICALS INC. (US) | 1988-07-06 | — | — | EP | disclosed |
| EP-0273309-A2 | 5-Aryl-3H-1,2,4-triazol-3-ones and their use in the treatment of neurodegenerative disorders | MERRELL DOW PHARMACEUTICALS INC. (US) | 1988-07-06 | — | — | EP | disclosed |
| EP-0273309-A2 | 5-Aryl-3H-1,2,4-triazol-3-ones and their use in the treatment of neurodegenerative disorders | MERRELL DOW PHARMACEUTICALS INC. (US) | 1988-07-06 | — | — | EP | disclosed |
| EP-0273310-A2 | 5-Aryl-3H-1,2,4-triazol-3-ones and their use as anticonvulsants | MERRELL PHARMACEUTICALS INC. (US) | 1988-07-06 | — | — | EP | disclosed |
| EP-0273310-A2 | 5-Aryl-3H-1,2,4-triazol-3-ones and their use as anticonvulsants | MERRELL PHARMACEUTICALS INC. (US) | 1988-07-06 | — | — | EP | disclosed |
| EP-0273310-A2 | 5-Aryl-3H-1,2,4-triazol-3-ones and their use as anticonvulsants | MERRELL PHARMACEUTICALS INC. (US) | 1988-07-06 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130190330-A1 | BISARYL-BONDED ARYLTRIAZOLONES AND USE THEREOF | NAT1, AADAC, TNNI3 | ACHE 2597/4885BACE1 1404/4885GPR84 3844/4885 |
| US-20160051518-A1 | BISARYL-BONDED ARYLTRIAZOLONES AND USE THEREOF | NAT1, AADAC, TNNI3 | ACHE 2597/4885BACE1 1404/4885GPR84 3844/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.